Literature DB >> 11504092

99mTc-(V)DMSA scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI.

V Papantoniou1, J Christodoulidou, E Papadaki, V Valotassiou, A Stipsanelli, A Louvrou, D Lazaris, M Sotiropoulou, G Pampouras, A Keramopoulos, S Michalas, C Zerva.   

Abstract

The purpose of this study was to evaluate and compare the diagnostic accuracy of pentavalent technetium-99m dimercaptosuccinic acid [99mTc-(V)DMSA] and 99mTc-methoxyisobutylisonitrile (MIBI) in the detection of primary breast cancer and metastatic lymph node involvement, and in the clarification of cases with indeterminate mammograms. Forty-one women (mean age+/-SD 55+/-7 years) referred for a suspicious breast lesion on physical examination and/or an abnormal mammogram underwent MIBI and (V)DMSA scintimammography (SMM) at separate sessions (48-h interval). Lateral prone and anterior supine images were obtained at 10 and 60 min after administration of 740-925 MBq of each tracer, in the arm contralateral to the breast lesion. The ipsilateral axillary region was also included in the field of view. The results of SMM and mammography were compared with histological findings. Breast cancer was histologically confirmed in 26 patients (mean diameter+/-SD 2.87+/-1.5 cm). Benign lesions were found in 15 patients (mean diameter+/-SD 2.04+/-2.7 cm). Mammography was definitely positive in 23/26 patients with breast cancer and indeterminate in 3/26 (sensitivity 88.4%). In benign lesions, mammography was true negative in 5/15 cases and indeterminate in 10/15 (specificity 33.3%). Both MIBI and (V)DMSA SMM detected 23/26 breast cancers (sensitivity 88.4%) and were true negative in 14/15 (specificity 93.3%). T/B ratios for breast cancer in MIBI and (V)DMSA scans were similar, and significantly higher than for benign lesions. MIBI correctly diagnosed 12/13 and (V)DMSA 11/13 cases in which the findings of mammography were indeterminate. In addition, (V)DMSA detected seven of eight cases of in situ ductal carcinoma (DCIS) associated with infiltrating carcinomas, while MIBI detected only two of these eight cases. (V)DSMA was also diffusely concentrated in benign lesions complicated by epithelial hyperplasia. Metastatic lymph node involvement was successfully imaged in 15/19 patients with metastatic disease by both agents (sensitivity 78.9%), while true-negative scans were observed in 19/22 (specificity 86.3%) patients with benign or malignant tumours without lymph node metastases. Linear regression analysis revealed a high coefficient of correlation between the (V)DMSA and the MIBI T/B ratios (r=0.8 P<0.001). We conclude that both (V)DMSA and MIBI show an excellent ability to detect breast cancer and its lymph node metastases. (V)DMSA also has a tendency to be diffusely and more intensely localised than MIBI in pre-invasive lesions, such as DCIS or epitheliosis, which are at risk of developing into malignancies. (V)DMSA could therefore provide a useful tool in the diagnosis of such lesions and possibly modify a predefined surgical plan. Finally, we believe that both tracers could offer an alternative method for elucidating nondiagnostic mammograms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504092     DOI: 10.1007/s002590100545

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  9 in total

1.  In vitro verification of the correlation of in vivo 99mTc-(V)DMSA uptake with cellular proliferation rate.

Authors:  Vassilios Papantoniou; Spyridon Tsiouris
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10       Impact factor: 9.236

Review 2.  Nuclear imaging of the breast: translating achievements in instrumentation into clinical use.

Authors:  Carrie B Hruska; Michael K O'Connor
Journal:  Med Phys       Date:  2013-05       Impact factor: 4.071

3.  Molecular breast imaging: an emerging modality for breast cancer screening.

Authors:  Michael K O'Connor
Journal:  Breast Cancer Manag       Date:  2015-01-01

4.  Pentavalent technetium-99m dimercaptosuccinic acid [99m Tc-(V)DMSA] brain scintitomography--a plausible non-invasive depicter of glioblastoma proliferation and therapy response.

Authors:  Spyridon Tsiouris; Ioannis Pirmettis; Theodoros Chatzipanagiotou; Nikolaos Ptohis; Vassilios Papantoniou
Journal:  J Neurooncol       Date:  2007-06-07       Impact factor: 4.130

5.  Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer.

Authors:  Vassilios J Papantoniou; Michael A Souvatzoglou; Varvara J Valotassiou; Androniki N Louvrou; Constantina Ambela; John Koutsikos; Dimitrios Lazaris; Julie K Christodoulidou; Maria G Sotiropoulou; Maria J Melissinou; Aris Perperoglou; Spyridon Tsiouris; Cherry J Zerva
Journal:  Breast Cancer Res       Date:  2003-12-11       Impact factor: 6.466

6.  Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography.

Authors:  Vassilios Papantoniou; Spyridon Tsiouris; Ekaterini Mainta; Varvara Valotassiou; Michael Souvatzoglou; Maria Sotiropoulou; Lydia Nakopoulou; Dimitrios Lazaris; Androniki Louvrou; Maria Melissinou; Artemis Tzannetaki; Ioannis Pirmettis; John Koutsikos; Cherry Zerva
Journal:  Breast Cancer Res       Date:  2004-11-08       Impact factor: 6.466

7.  Role of 99mTc-(V)DMSA in detecting tumor cell proliferation.

Authors:  Fatma Al-Saeedi
Journal:  Anal Chem Insights       Date:  2007-12-13

8.  Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer.

Authors:  Michael K O'Connor; Melissa M B Morrow; Katie N Hunt; Judy C Boughey; Dietlind L Wahner-Roedler; Amy Lynn Conners; Deborah J Rhodes; Carrie B Hruska
Journal:  EJNMMI Res       Date:  2017-01-14       Impact factor: 3.138

9.  Assessment of tracer 99mTc(V)-DMSA uptake as a measure of tumor cell proliferation in vitro.

Authors:  Fatma J Al-Saeedi; Princy M Mathew; Yunus A Luqmani
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.